Eli Lilly Acquires Merida Biosciences for $2.9 Billion to Expand Autoimmune Drug Pipeline
Eli Lilly has announced the acquisition of Merida Biosciences for approximately $2.9 billion, aiming to strengthen its drug pipeline in autoimmune and allergic disease treatments. Merida is developing therapies that target specific pathogenic autoantibodies without broadly suppressing immune systems, a novel approach compared to many existing treatments. The company's lead candidate, MER511, is currently in Phase 1 trials for Graves' disease and thyroid eye disease. This acquisition marks another strategic move by Lilly as it continues its aggressive expansion strategy since early 2023 with over two dozen acquisitions across various therapeutic areas. Much of this financial capacity stems from the blockbuster success of Lilly's GLP-1 drug tirzepatide, which generated $9.9 billion in revenue for Mounjaro and $4.9 billion for Zepbound during Q2 2026. The healthcare sector remains a strong investment area due to aging populations, rising global wealth, and consistent demand regardless of economic conditions.
Tickers: $LLY